Dossier assessment
Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of pulmonary arterial hypertension in adult patients with WHO Functional Class II to III, to improve exercise capacity
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-03-06 A G-BA decision was published.
Project details
- Project no.
- A24-96
- Commission
- Commission awarded on 15.09.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A24-96_en
Connected Projects
-
Addendum
Sotatercept (pulmonary arterial hypertension) – Addendum to Project A24-96
Status: Commission completed
-
Dossier assessment
Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed